Clinical Research Directory

Inclusion Criteria: * Social anxiety disorder as defined in DSM-5 * Full understanding of the protocol * Obtaining informed consent from study subjects before or at inclusion at the latest * Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent) Exclusion Criteria: * Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy * Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis * Long-term corticotherapy * History of significant head injury, defined by loss of consciousness * Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder * Suicidal risk evaluated as moderate to high in the MINI questionnaire * initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including: 1. antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic 2. anxiolytic drugs including benzodiazepines and anti-histamine 3. antipsychotic drugs * Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions) * Pregnancy or breastfeeding. * Ongoing hospitalization without consent (decision of a third-party: medical, justice)